Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results

Infection Control and Hospital Epidemiology

Volumn 30, Issue 4, 2009, Pages 392-395

  Pollock, Nira R ^a   Kashino, Suely S ^b   Napolitano, Danielle R ^b   Sloutsky, Alex ^c   Joshi, Swati ^c   Guillet, Jasmine ^c   Wong, Michael ^a   Nardell, Edward ^d   Campos Neto, Antonio ^b,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b FORSYTH INSTITUTE   (United States)

^c Massachusetts State Laboratory   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; ISONIAZID; PYRIDOXINE; TUBERCULIN;

ADULT; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; FEMALE; HEALTH CARE PERSONNEL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; OUTCOME ASSESSMENT; QUANTIFERON TUBERCULOSIS GOLD ASSAY; QUANTITATIVE ASSAY; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; INTERFERON-GAMMA; ISONIAZID; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REAGENT KITS, DIAGNOSTIC; SKIN TESTS; TREATMENT OUTCOME; TUBERCULIN; TUBERCULOSIS;

EID: 63449105664     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/596606     Document Type: Article

References (11)

1. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54(RR-15):49-55.
2. Jensen PA, Lambert LA, Iademarco MF, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005;54:1-141.
3. QuantiFERON-TB Gold [package insert]. Document no. 05980000C. Victoria, Australia: Cellestis; 2006.
4. Napolitano DR, Pollock N, Kashino SS, Rodrigues V Jr, Campos-Neto A. Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis. Clin Vaccine Immunol 2008; 15:638-643.
5. Public Health Agency of Canada. International tuberculosis incidence rates. March 31, 2008. Available at: http://www.phac-aspc.gc.ca/tbpc -latb/itir-e.html. Accessed September 1, 2008.
6. Wilkinson KA, Kon OM, Newton SM, et al. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 2006; 193:354-359.
7. Chee CB, KhinMar KW, Gan SH, Barkham TM, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 2007; 175:282-287.
8. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 174:831-839.
9. Pai M., Joshi R, Dogra S, et al. Persistently elevated T cell interferon-γ responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 2006; 1:7.
10. Higuchi K, Harada N, Mori. T. Interferon-γ responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008; 13:468-472.
11. Goletti D, Parracino MP, Butera O, et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 2007; 8:5.